Phase I Clinical Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of CW002

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

136 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2013-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test the safety and efficacy of an investigational neuromuscular blocking agent called CW002 and to document its effects on healthy adult volunteers. A neuromuscular blocking agent is a drug that temporarily prevents muscles from moving. CW002 has not yet been approved by the Food and Drug Administration (FDA).

Usually, neuromuscular blocking agents are used together with other drugs that put people completely "asleep". These drugs allow doctors to place a breathing tube in the airway, stop muscles from moving during surgical operations, and allow ventilation (movement of air).

This research is being done because CW002 is expected to act quickly and to provide a muscle block of intermediate (not too long, not too short) duration. The researchers would like to test increasing doses of CW002 that can be given without causing severe side effects. If shown to be both safe and effective, such a compound would be useful in surgical procedures and could improve future anesthetic care.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Reversal of Moderate or Superficial Neuromuscular Blockade Induced by Cisatracurium

NCT04920682

Neostigmine Neuromuscular Blocking Agents Muscle Weakness

COMPLETED PHASE4

Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity

NCT05311215

Spasticity

UNKNOWN PHASE2

Study of the Oral Treatment MTR-601 in Cervical Dystonia

NCT06830642

Cervical Dystonia

SUSPENDED PHASE2

Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

NCT05206513

Dyskinesia Cerebral Palsy

ACTIVE_NOT_RECRUITING PHASE3

Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury

NCT01683838

Spinal Cord Injury Muscle Spasticity

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Neuromuscular blocking agents are especially important in intubation (insertion of breathing tube into the windpipe) because a quick and effective muscle block is needed to promptly complete the process and secure the airway. In addition, being able to rapidly reverse a blocking agent is desirable so that the patient can breathe on his/her own as soon as possible.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part I

Ascending dose tolerance, PK, and estimation of ED95 for CW 002

Group Type EXPERIMENTAL

CW 002

Intervention Type DRUG

For Cohort 1, subjects receive a single bolus of 0.02 mg/kg CW 002 (i.v.) and neuromuscular function will be allowed to recover spontaneously for at least 5 half-lives.

For Cohort 2, an estimated ED50 bolus dose of CW 002 (approximately 0.03 mg/kg) will be given i.v. followed by a second bolus of the same dosage\*.

For Cohort 3, an estimated ED 75 bolus dose of CW 002 (approximately 0.04 mg/kg) will be given i.v. followed by a second bolus of the same dosage \*.

For Cohort IV, an estimated ED 90 bolus dose of CW 002 (approximately 0.06 mg/kg) will be given i.v. followed by a second bolus of the same dosage\*.

\*For Cohorts 2-4, a second bolus dose will be administered following a minimum of 5 half-lives of CW002 (based on PK data from Cohort 1).

Part II

Safety, efficacy and PK of increasing bolus doses and infusions of CW 002, and exploration of Neostigmine reversal

Group Type EXPERIMENTAL

CW 002

Intervention Type DRUG

Subjects receive an initial ascending bolus dose of CW 002 injection, and a second bolus followed by a continuous infusion initiated at the point of 25% recovery of twitch response. Infusion rate will be adjusted to maintain 97%- 99% suppression of twitch, but to avoid complete neuromuscular block. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.

Cohort 5- subject receives 2.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 30 min infusion of 2-10 mcg/kg/min of CW 002

Cohort 6 - subject receives 3.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 60 min infusion of 2-10 mcg/kg/min of CW 002

Cohort 7 - subject receives 4.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 90 min infusion of 2-10 mcg/kg/min of CW 002

Bolus doses of ED95 are determined in Part I of the study.

Part III

Intubation with CW 002 and Neostigmine reversal

Group Type EXPERIMENTAL

CW 002

Intervention Type DRUG

In Part III, safety, intubation efficacy, and PK will be evaluated in 2 cohorts (Cohorts 8 and 9) of 6 subjects each, who will undergo endotracheal intubation at 60 or 90 seconds after a bolus dose of CW002 injection at 3 to 4 times the ED95. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.

Cohort 8 - subject receives 3.0x ED95 dose of CW 002, and intubation attempt is made 90 seconds post-bolus.

Cohort 9 - subject receives 4.0x ED95 dose of CW 002, and intubation attempt is made 60 seconds post-bolus.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CW 002

For Cohort 1, subjects receive a single bolus of 0.02 mg/kg CW 002 (i.v.) and neuromuscular function will be allowed to recover spontaneously for at least 5 half-lives.

For Cohort 2, an estimated ED50 bolus dose of CW 002 (approximately 0.03 mg/kg) will be given i.v. followed by a second bolus of the same dosage\*.

For Cohort 3, an estimated ED 75 bolus dose of CW 002 (approximately 0.04 mg/kg) will be given i.v. followed by a second bolus of the same dosage \*.

For Cohort IV, an estimated ED 90 bolus dose of CW 002 (approximately 0.06 mg/kg) will be given i.v. followed by a second bolus of the same dosage\*.

\*For Cohorts 2-4, a second bolus dose will be administered following a minimum of 5 half-lives of CW002 (based on PK data from Cohort 1).

Intervention Type DRUG

CW 002

Subjects receive an initial ascending bolus dose of CW 002 injection, and a second bolus followed by a continuous infusion initiated at the point of 25% recovery of twitch response. Infusion rate will be adjusted to maintain 97%- 99% suppression of twitch, but to avoid complete neuromuscular block. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.

Cohort 5- subject receives 2.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 30 min infusion of 2-10 mcg/kg/min of CW 002

Cohort 6 - subject receives 3.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 60 min infusion of 2-10 mcg/kg/min of CW 002

Cohort 7 - subject receives 4.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 90 min infusion of 2-10 mcg/kg/min of CW 002

Bolus doses of ED95 are determined in Part I of the study.

Intervention Type DRUG

CW 002

In Part III, safety, intubation efficacy, and PK will be evaluated in 2 cohorts (Cohorts 8 and 9) of 6 subjects each, who will undergo endotracheal intubation at 60 or 90 seconds after a bolus dose of CW002 injection at 3 to 4 times the ED95. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.

Cohort 8 - subject receives 3.0x ED95 dose of CW 002, and intubation attempt is made 90 seconds post-bolus.

Cohort 9 - subject receives 4.0x ED95 dose of CW 002, and intubation attempt is made 60 seconds post-bolus.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is male or female in good health (ASA I) between the ages of 18 and 49 years inclusive, with no concurrent disease or illness. Females must be non pregnant, non lactating, and practicing an acceptable method of birth control (e.g., barrier, oral contraceptive, vasectomized partner, abstinence) or be surgically sterile or post menopausal. A pregnancy test will be performed at Screening and on Day 1 to confirm non-pregnant status of female subjects.
* Weighs between 55 and 95 kg, inclusive, and has a body mass index (BMI) between 18 and 30 kg/m2 (BMI calculated as weight in kg/\[height in m\]2 )
* Agrees to abstain from taking any dietary supplements or non-prescription drugs (except for multivitamins or as authorized by the Investigator and Medical Monitor) for 3 days prior to Baseline through Follow-Up
* Agrees to abstain from taking any prescription drugs (except as authorized by the Investigator and Medical Monitor) during the 14 days prior to Baseline through Follow-Up
* Agrees to abstain from consuming alcohol-containing beverages for 3 days prior to Baseline through Follow-up
* Is in good health (ASA Class I) based on medical history and clinically acceptable results on the following assessments: physical examination, vital signs, 12 lead ECG, clinical chemistry, hematology/coagulation, and urinalysis. Seated systolic BP must be \> 90 mmHg and ≤ 140 mmHg and seated diastolic BP must be \> 50 mmHg and ≤ 90 mmHg at Screening and Baseline
* Has no history of cardiovascular, pulmonary, renal, hepatic, central nervous system, or neuromuscular disease, or history of asthma or diabetes (ASA Class I)
* Is able to communicate effectively with study personnel and is considered reliable, willing, and cooperative in terms of compliance with the protocol requirements
* Voluntarily gives written informed consent to participate in the study
* Has available a responsible adult who has agreed to transport the subject home

Exclusion Criteria

* Has any current acute or chronic disease
* Has a history of any clinically important medical disorder including any of the following: cardiovascular, pulmonary, hepatic, renal, CNS or neuromuscular disease, asthma or diabetes
* Has a history of anaphylaxis, a documented hypersensitivity reaction, or a clinically important idiosyncratic reaction to any drug
* Has a history of neuromuscular junction disease (e.g., myotonic dystrophy, polio, myasthenia gravis, botulism poisoning)
* Has a history of malignant hyperthermia
* Has had recent (within 2 weeks) use of aminoglycoside antibiotics or corticosteroids
* Has a history of sleep apnea
* Has a history of prior anesthetic complications
* Has any history of asthma requiring management for reactive airway disease
* Has a history of an anatomic airway abnormality or indication of an airway abnormality assessed during the Screening airway examination that could interfere with laryngoscopy or tracheal intubation
* Has a history of Human Immunodeficiency Virus (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS), or has a history of viral hepatitis (other than Hepatitis A)
* Has a history of malignancy within the past 5 years, with the exception of successfully treated non-metastatic basal cell or squamous cell carcinomas of the skin and/or localized carcinoma in situ of the cervix
* Has a predisposing condition that could interfere with the absorption, distribution, metabolism, or excretion of drugs or any condition that may confound the PK analyses, particularly hepatic or renal disease
* Has received another investigational drug within 30 days prior to the Screening Visit
* Has a history of alcohol abuse (regularly drinks more than 4 units of alcohol per day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit) and/or evidence of any use within 3 days prior to Baseline
* Has a history or current evidence of abuse of licit or illicit drug substances or a positive urine drug screen for drugs of abuse
* Currently uses tobacco-containing products or has a history of tobacco use within 6 months prior to the Screening Visit
* Has donated blood or plasma within 60 days prior to the Screening Visit
* Has an abnormal bleeding tendency

Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes